Look up one drug

Ontario coverage, price, criteria word for word, Health Canada status and shortages for one product

Patient plan: look up a medication list

PHENYTOIN (DIPHENYLHYDANTOIN)

All products: general benefit

Other products in the same Health Canada class (N03A, N03AB) — coverage varies; not interchangeable

  • Phenytoin diphenylhydantoin (Dilantin): general benefit, Limited Use 481, 657
  • Carbamazepine (Tegretol): general benefit, Limited Use, Not a benefit, Listing status unconfirmed
  • Clonazepam (Rivotril): general benefit
  • Divalproex (Epival): general benefit
  • Ethosuximide (Zarontin): general benefit
  • Lamotrigine (Lamictal): general benefit

14 more in the class list below

Dilantin-125 Suspension · DIN 00023450 · 25mg/mL · oral liquid

General benefit; Health Canada lists this DIN as Cancelled post market since 2025-12-09 — choose a marketed DIN from the same-category list.Discontinued 2025-12-09 · checked 2026-09-20
StatusGeneral benefit; Health Canada lists this DIN as Cancelled post market since 2025-12-09 — choose a marketed DIN from the same-category list.
Write on scriptno code needed; Health Canada lists this DIN as Cancelled post market since 2025-12-09 — choose a marketed DIN from the same-category list.
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
1 brand, same coverage
Dilantin-125 Suspension · DIN 00023450 Manufacturer: Upjohn Canada ULC; listing date 1996-10-01 Health Canada: Cancelled post market since 2025-12-09 · brand DILANTIN-125 SUSPENSION · ATC N03AB02 PHENYTOIN · form Suspension · route Oral · ingredients PHENYTOIN 125 MG/5ML · company Bgp pharma ulc · schedule Prescription
Check this DIN again · Health Canada product record

Ministry pays: $0.0444 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=613 · Verify on the e-Formulary ↗ (DIN 00023450)

Source record
The source extract's flag for this DIN is unclear — confirm on the e-Formulary before prescribing (DIN 00023450). DIN 00023450: Dilantin-125 Suspension Raw flags: dinStatus=E, sec3=Y Item: 281200002; group id 439; item number 1098; lccId None; manufacturer id UJC Source form: O/L; strength: 25mg/mL Recorded listing: General benefit; DIN status E, meaning unconfirmed Source prices (unrounded): $0.0697; ministry $0.0444 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=00023450 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=613
Interchangeable products
Taro-Phenytoin · DIN 02250896 · $0.0444
Shortage status: not checked (no credentials)
Health Canada lists this DIN as Cancelled post market since 2025-12-09 — choose a marketed DIN from the same-category list.
Other drugs in the same formulary class (28:12 Anticonvulsants) and how they are covered

Matched class: 28:12 Anticonvulsants

Drug-class inventory only. Lists recorded Ontario formulary products, not every Canadian medication; does not recommend treatment. Covered without a code on the Ontario formulary: CLONAZEPAM, DIVALPROEX SODIUM, ETHOSUXIMIDE, LAMOTRIGINE, VALPROATE SODIUM Some products covered without a code (check the product listing): CARBAMAZEPINE, GABAPENTIN, PHENYTOIN (DIPHENYLHYDANTOIN) SODIUM, PREGABALIN, PRIMIDONE, TOPIRAMATE, VALPROIC ACID 28:12 Anticonvulsants

PHENYTOIN (DIPHENYLHYDANTOIN) SODIUM

· 4 products · General benefit (3), Limited Use, codes 481, 657 (1) · strengths: 30mg, 100mg, 50mg/mL · Cap, Inj Sol (Preservative Free)

CARBAMAZEPINE

· 15 products · Listed, not a benefit (3), General benefit (6), Temporary benefit (2), Limited Use, codes 67 (4) · strengths: 100mg, 200mg, 400mg, 100mg/5mL · Chew Tab, ER Tab, LA Tab, Oral Susp, Tab

CLONAZEPAM

· 9 products · General benefit · strengths: 0.5mg, 2mg · Tab

DIVALPROEX SODIUM

· 9 products · General benefit · strengths: 125mg, 250mg, 500mg · Ent Tab

ETHOSUXIMIDE

· 4 products · General benefit · strengths: 250mg, 50mg/mL · Cap, O/L

LAMOTRIGINE

· 28 products · General benefit · strengths: 25mg, 100mg, 150mg · Tab

PRIMIDONE

· 4 products · General benefit (2), Listed, not a benefit (2) · strengths: 125mg, 250mg · Tab

TOPIRAMATE

· 54 products · Limited Use, codes 321 (2), Off-Formulary Interchangeable, not an ODB benefit (3), General benefit (49) · strengths: 15mg, 25mg, 50mg, 100mg, 200mg · Sprinkle Cap, Tab

VALPROATE SODIUM

· 5 products · General benefit · strengths: 50mg/mL · O/L

VALPROIC ACID

· 5 products · Listed, not a benefit (2), General benefit (3) · strengths: 250mg, 500mg · Cap, Ent Cap

BRIVARACETAM

· 12 products · Limited Use, codes 548 · strengths: 10mg, 25mg, 50mg, 75mg, 100mg · Tab

CENOBAMATE

· 9 products · Limited Use, codes 719 · strengths: 12.5mg, 25mg, 50mg, 100mg, 150mg, 200mg, 12.5mg & 25mg, 50mg & 100mg, 150mg & 200mg · Tab, Tab - (Starter Kit) Source: formulary-ed43-front-matter.txt Part V; ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26; class 28:12 and 11 more
Full class listing Related classes: 28:08 Analgesics, 28:10 Opiate Antagonists, 28:16 Psychotherapeutic Agents, 28:20 C.N.S. Stimulants, 28:24 Sedatives and Hypnotics, 28:36 Antiparkinsonian Agents, 28:92 Miscellaneous Central Nervous System Drugs Same formulary class, not same indication: class membership alone does not establish equivalent uses.
What the Health Canada label says it is for
1 INDICATIONS DILANTIN INFATABS (phenytoin chewable tablets), DILANTIN-30 SUSPENSION and DILANTIN- 125 SUSPENSION (phenytoin oral suspensions) are indicated for: • the control of generalized tonic-clonic (grand mal) and complex partial (psychomotor, temporal lobe) seizures. Phenytoin is not effective for absence (petit mal) seizures, and not indicated for seizures due to hypoglycemic or other metabolic causes. 1.1 Pediatrics Pediatrics (< 18 years of age): See 4.2 Recommended Dose and Dosage Adjustments, Pediatrics. 1.2 Geriatrics Evidence from clinical studies and experience suggests that use in the geriatric population is associated with differences in safety or effectiveness. See 4.2 Recommended Dose and Dosage Adjustments, Geriatrics. https://pdf.hres.ca/dpd_pm/00071910.PDF PM date: August 2, 2023 Source product: DILANTIN INFATABS; DIN 00023698; fetched 2026-09-10 Product monograph posted by Health Canada; excerpt for lookup only.